Bioperfectus and Red Cross Taizhou Raised Donation of 100,000 COVID-19 Self Antigen Tests to Hongkong

Company news
2022-04-25

On April 19, under the coordination of the Hong Kong and Macao Affairs Office of Jiangsu Province, the Provincial Health and Wellness Commission, and the relevant departments of the Central Government, in a joint effort with the Red Cross Society of China Taizhou Branch, 100,000 COVID-19 antigen self-test kits were donated to the Hong Kong community by Jiangsu Bioperfectus Technologies Co., Ltd. 

 

The Hong Kong Community Anti-Coronavirus Link accepted this batch of supplies and distributed them to the Hong Kong community. The Hong Kong Community Anti-Coronavirus Link person said, “We are currently fighting against the epidemic and actively cooperating with the Hong Kong Special Administrative Region’s anti-epidemic measures to overcome the outbreak quickly. The COVID-19 self-antigen tests donated by Bioperfectus are very timely; in the following days, the kits will be distributed to Hong Kong residents as soon as possible.”

 

Since the outbreak of the COVID-19 pandemic, Bioperfectus has established in-depth cooperation with NGOs, including Global FUND, UNOPS, FIND, etc., to assist the recovery of economies from the COVID-19 pandemic. So far, Bioperfectus in-vitro diagnostics products have been distributed to over 90 countries and regions around the globe.

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14